Biocon Limited reported a 56.8 percent year-on-year decline in consolidated net profit for the fourth quarter of FY26, primarily due to an exceptional item charge of ₹80.4 crore during the period. Despite the sharp drop in profitability, the company posted steady revenue growth, supported by strong momentum in its biosimilars and generics businesses. Biocon’s consolidated net profit for Q4FY26 stood at ₹198.6 crore, while revenue from operations increased 13 per cent year-on-year to ₹4,517 crore, including licensing income recognised during the quarter.
Biosimilars Segment Leads Revenue Growth
The company’s biosimilars business emerged as the key growth driver during the quarter. Revenue from the segment rose 16 per cent year-on-year to ₹2,756 crore, reflecting strong demand across advanced and emerging markets. Meanwhile, the Contract Development and Manufacturing Organisation (CDMO) business recorded moderate growth of 3 per cent year-on-year, reaching ₹1,037 crore. However, the generics segment witnessed pressure during the quarter, with revenue declining 17 per cent year-on-year to ₹847 crore.
Biocon Focuses on Profitability and Global Expansion
Kiran Mazumdar-Shaw said the integration of the company’s biologics business has strengthened Biocon’s financial and operational position. “The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. We are now focused on profitability enhancement and long-term value creation,” she stated. The company also continued to invest in innovation and product development, making a net research and development (R&D) investment of ₹277 crore during the quarter.
Biocon Completes Integration of Biologics Business
During FY26, Biocon completed the integration of its biologics arm within the broader Biocon group structure. The integration, announced in December 2025, was aimed at creating a unified global biopharmaceutical company by combining Biocon’s generics operations with Biocon Biologics’ specialised biosimilars portfolio.
The restructuring was also intended to eliminate the holding company discount linked to Biocon Biologics and unlock greater shareholder value. To support the acquisition and integration process, the company raised nearly ₹4,500 crore through a qualified institutional placement (QIP).
Company Shifts Strategy Toward Consolidation
Shreehas Tambe, CEO and Managing Director, Biocon Limited said the company witnessed strong growth in advanced markets along with key tender wins across emerging regions. “Growth was led by strong performance in advanced markets and key tender wins across emerging markets. With the integration now complete, we shift gears in FY27 from the ‘Preserve’ phase of our strategy to ‘Consolidate’, as we set up the business for sustainable growth,” he said. As reported by thehindubusinessline.com, going forward, Biocon plans to focus on operational consolidation, profitability improvement and expanding its global presence in the biosimilars and specialty pharmaceuticals market.
